Keiretsu Capital appeared to be the VC, which was created in 2007. The main department of described VC is located in the Seattle. The venture was found in North America in United States.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Keiretsu Capital, startups are often financed by Keiretsu Forum, Portland Seed Fund, Band of Angels. The meaningful sponsors for the fund in investment in the same round are Keiretsu Forum, Band of Angels, Sand Hill Angels. In the next rounds fund is usually obtained by Puget Sound Venture Club, Keiretsu Forum Northwest, Tech Coast Angels.
The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are SaaS, Internet. Among the most popular portfolio startups of the fund, we may highlight Transform, Inc., Alpin, Perkville. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
The usual things for fund are deals in the range of 1 - 5 millions dollars. The top activity for fund was in 2016. The fund is constantly included in 7-12 investment rounds annually. Considering the real fund results, this VC is 19 percentage points less often commits exit comparing to other organizations. When the investment is from Keiretsu Capital the average startup value is 5-10 millions dollars. This Keiretsu Capital works on 25 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2019.
The fund was created by Matthew Le Merle, Matthew Le Merle, Nathan McDonald, Randy Williams. We also calculated 12 valuable employees in our database.
Related Funds
Funds with similar focus
Fund Name | Location |
Advent France Biotechnology | France, Ile-de-France, Paris |
Allrise Capital | - |
Anhui University of Technology | Anhui, China, Maanshan |
Desert Sky Holdings | California, Los Angeles, United States |
Eldorado Gold Corp. | British Columbia, Canada, Vancouver |
Full Moon Investments | Cary, North Carolina, United States |
Inversiones Montferrat | - |
JSTV.com | China, Jiangsu, Nanjing |
National Research Council of Canada Industrial Research Assistance Program | Canada, Ontario, Ottawa |
Radiant Haroti | India, Jaipur, Rajasthan |
Shanghai Side Weisi Chuangye Touzi Guanli Youxian Gongsi | China, Shanghai |
Stellar Development Foundation | California, San Francisco, United States |
sxw100.com | Beijing, China, Haidian |
TGVest Capital | Taipei, Taiwan |
Toho Holdings | Japan, Tokyo |
Toyota Systems | Aichi Prefecture, Japan, Nagoya |
Wistron Corporation | Taipei, Taiwan |
ZHEXINIT | China, Hangzhou, Zhejiang |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
MiClient | $507K | 12 Aug 2024 | Gurgaon, Haryana, India | ||
Healionics | $5M | 07 Nov 2023 | Seattle, Washington, United States | ||
Clensta | $9M | 10 Jul 2023 | New Delhi, Delhi, India | ||
Another Tomorrow | 19 May 2023 | New York, New York, United States | |||
Hotel Communication Network | 12 May 2023 | (Old) Ottawa, Ontario, Canada | |||
Turn Technologies, Inc. | 27 Apr 2023 | Chicago, Illinois, United States | |||
ActX | 31 Dec 2022 | Seattle, Washington, United States | |||
DecisionNext | 02 Dec 2022 | San Francisco, California, United States | |||
FEMSelect | $9M | 19 Oct 2022 | Israel, Center District, Israel |
– Seattle-based medical technology company Healionics raised $4.7m funding.
– The round was led by Keiretsu Capital and joined by others.
– It will be used to complete a second human study and obtain FDA clearance.
– Healionics is a clinical-stage company addressing the need for means of bloodstream access to perform dialysis in patients with kidney failure.
– The company announced the closing of a $4.7M equity financing led by Keiretsu Capital.
– The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.
– The new investment will be used to complete an ongoing human study and to obtain FDA market clearance.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
MiClient | $507K | 12 Aug 2024 | Gurgaon, Haryana, India | ||
Healionics | $5M | 07 Nov 2023 | Seattle, Washington, United States | ||
Clensta | $9M | 10 Jul 2023 | New Delhi, Delhi, India | ||
Another Tomorrow | 19 May 2023 | New York, New York, United States | |||
Hotel Communication Network | 12 May 2023 | (Old) Ottawa, Ontario, Canada | |||
Turn Technologies, Inc. | 27 Apr 2023 | Chicago, Illinois, United States | |||
ActX | 31 Dec 2022 | Seattle, Washington, United States | |||
DecisionNext | 02 Dec 2022 | San Francisco, California, United States | |||
FEMSelect | $9M | 19 Oct 2022 | Israel, Center District, Israel |